Taking stock of the drug industry, from the lab to the medicine chestMay 5, 2025Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer Adobe Scientists question NIH project's use of 20th century technology to make a universal flu vaccine Scientists question spending $500 million to use whole killed viruses — an approach pioneered in the last century — for new vaccines By Helen Branswell STAT+ | Opinion: Bristol Myers Squibb CEO: Pharmaceutical innovation requires bold yet predictable U.S. policy Just as government policies have bolstered U.S. leadership in the pharmaceutical industry, they can also destroy it, writes BMS' Christopher Boerner. By Christopher Boerner STAT+ | At AACR, leading cancer researchers urge colleagues to 'fight for your science' At one of the largest cancer conferences in the world, researchers spoke with unusual boldness about advocating for their work. By Angus Chen Agnese Morganti for STAT STAT+ | As financial prospects for gene therapies dim, an ambitious charity picks up the torch Telethon Foundation of Milan hopes to serve as a model for others looking to deliver gene therapies to patients when drugmakers are not. By Andrew Joseph STAT+ | Opinion: A court decision on lab-developed tests sets a dangerous precedent A district court ruling asserts that the FDA does not have responsibility for the authorization and oversight of lab-developed tests. By Kushal T. Kadakia, Joseph S. Ross, and Reshma Ramachandran More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2025, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments